OTC Markets OTCQB - Delayed Quote USD

Lobe Sciences Ltd. (LOBEF)

0.0022
-0.0193
(-89.77%)
At close: May 16 at 4:00:00 PM EDT
Loading Chart for LOBEF
  • Previous Close 0.0215
  • Open 0.0184
  • Bid 0.0170 x --
  • Ask 0.0186 x --
  • Day's Range 0.0184 - 0.0215
  • 52 Week Range 0.0008 - 0.0215
  • Volume 19,000
  • Avg. Volume 65,021
  • Market Cap (intraday) 423,834
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) --
  • EPS (TTM) -0.0300
  • Earnings Date Jul 24, 2025 - Jul 28, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Lobe Sciences Ltd., a biopharmaceutical company, engages in the research and development using sub-hallucinatory doses of proprietary psychedelic compounds to improve brain and mental health, and wellness in Canada. The company was formerly known as Greenstar Biosciences Corp. and changed its name to Lobe Sciences Ltd. in November 2020. Lobe Sciences Ltd. was founded in 2018 and is headquartered in Vancouver, Canada.

www.lobesciences.com

--

Full Time Employees

August 31

Fiscal Year Ends

Recent News: LOBEF

View More

Performance Overview: LOBEF

Trailing total returns as of 5/16/2025, which may include dividends or other distributions. Benchmark is S&P/TSX Composite index (^GSPTSE) .

YTD Return

LOBEF
46.67%
S&P/TSX Composite index (^GSPTSE)
5.49%

1-Year Return

LOBEF
46.67%
S&P/TSX Composite index (^GSPTSE)
16.47%

3-Year Return

LOBEF
87.64%
S&P/TSX Composite index (^GSPTSE)
28.53%

5-Year Return

LOBEF
87.64%
S&P/TSX Composite index (^GSPTSE)
77.42%

Compare To: LOBEF

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: LOBEF

View More

Valuation Measures

Annual
As of 2/3/2025
  • Market Cap

    3.45M

  • Enterprise Value

    4.98M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    25.99

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    42.57

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    --

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    --

  • Diluted EPS (ttm)

    -0.0300

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    --

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    --

Research Analysis: LOBEF

View More

Company Insights: LOBEF

Research Reports: LOBEF

View More

People Also Watch